Download Citation on ResearchGate | Hemoglobinuria paroxística nocturna | Paroxysmal nocturnal hemoglobinuria is a rare acquired chronic hemolytic anemia. La hemoglobinuria paroxística nocturna (HPN) es una enfermedad clonal de las células progenitoras hematopoyéticas originada por la mutación adquirida del. TRATAMIENTO DE LA HEMOGLOBINURIA PAROXISTICA NOCTURNA CON GLOBULINA ANTILINFOCITARIA. Revista de Investigacion Clinica, 45(5).

Author: Sarr Mazulabar
Country: South Africa
Language: English (Spanish)
Genre: Business
Published (Last): 5 March 2016
Pages: 463
PDF File Size: 12.70 Mb
ePub File Size: 17.97 Mb
ISBN: 723-3-13282-198-8
Downloads: 48603
Price: Free* [*Free Regsitration Required]
Uploader: Dorn

From Wikipedia, the free encyclopedia. These include patients with unexplained thrombosis who are young, have thrombosis in an unusual site e. PY – Y1 – N2 – Objective. The dual pathogenesis of paroxysmal nocturnal hemoglobinuria. Deficient surface expression of glycosylphosphatidylinositol-anchored proteins in B cell lines established from patients with paroxysmal pwroxistica hemoglobinuria.

This is now an obsolete test for diagnosing PNH due to its low sensitivity and specificity. The mean survival was found to be 15 years. Deficient biosynthesis of N-acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosyl phosphatidylinositol anchor biosynthesis, in cell nocgurna established from patients with paroxysmal nocturnal hemogpobinuria.

CS1 German-language sources de CS1 Italian-language sources it Infobox medical condition new All articles with unsourced statements Articles with unsourced statements from January PNH is characterized by complement-mediated hemolysis and cloned expansion of affected cells of various hematopoietic lineages that are thought to be derived from an abnormal multipotential hematopoietic stem cell Rosse, Treatment of severe aplastic anemia with antithymocyte globulin ADG and cyclosporin leads to psroxistica remission in a large noctuna of patients.

Forty percent of people with PNH develop thrombosis a blood clot at some point in their illness. Risk factors affecting patients in the French population diagnosed by a positive Ham test were used in this multivariate analysis. We need long-term secure funding to provide you the information that you need at your fingertips.

Both the RH variant and wildtype C5 caused classic pathway hemolysis in vitro, but only wildtype C5 bound to and was blocked by eculizumab. Common variable immunodeficiency ICF syndrome. Dtsch Med Wochenschr in German. Since that time, short and mid term studies of patients on eculizumab demonstrate that the drug returns the patient to a normal life expectancy, improves quality of life, and decreases the need for blood transfusions.


Antilymphocyte globulin therapy for paroxysmal nocturnal hemoglobinuria

PNH red blood cells also were identified at a frequency of 8 per million. Nofturna mutation in the PIGA gene was identified in each of the 4.


Revista de Investigacion ClinicaVol. Translated title of the contribution Antilymphocyte globulin therapy for paroxysmal nocturnal hemoglobinuria Language Spanish Pages Number of pages 5 Journal Revista de Investigacion Clinica Volume 45 Issue number 5 State Published – Externally published Yes. Rosse indicated that all cases of PNH appear to have a defect in the PIGA gene, but the causative mutation has in all instances been unique.

Guía Clínica para diagnóstico y tratamiento de Hemoglobinuria Paroxística Nocturna

Paroxysmal nocturnal hemoglobinuria and the glycosylphosphatidylinositol anchor. Since the complement cascade attacks the red blood cells within the blood vessels of the circulatory systemthe red blood cell destruction hemolysis is considered an intravascular hemolytic anemia. Keywords antilymphocyte globulin therapy paroxysmal nocturnal hemoglobinuria. In this case, anemia may be caused by insufficient red blood cell production in addition to the hemolysis. The Cochrane Database of Systematic Reviews.

Revista de Investigacion Clinica45 5 All 4 clones had an entirely separate mutational basis. Episodes of thrombosis are treated as they would in other patients, but, given that PNH is a persisting underlying cause, it is likely that treatment with warfarin or similar drugs needs to be continued long-term after an episode of thrombosis.

They demonstrated a somatic point mutation in 4 cases which, with the 2 mutations reported by Takeda et al. People on eculizumab are strongly advised to receive meningococcal vaccination at least two weeks prior to starting therapy and to consider preventative antibiotics for the duration of treatment.

The clinical association between PNH and acquired aplastic anemia AAAand the observation that, as in AAA, PNH patients have decreased hematopoietic progenitors, may be taken to suggest a common pathogenetic process. Clinical and Translational Science. For instance, if the damage was caused by autoreactive T cells or by natural killer cells, as has been suggested to be the case in aplastic anemia, one could speculate that this happens by virtue of these cells triggering an apoptotic pathway by interacting with a GPI-linked molecule normally present on the surface of hematopoietic stem cells.

Transfusion therapy may be needed; in addition to correcting significant anemiathis suppresses the production of PNH cells by the bone marrow, and indirectly the severity of the hemolysis. PNH is the only hemolytic anemia caused by an acquired rather than inherited intrinsic defect in the cell membrane deficiency of glycophosphatidylinositol leading to the absence of protective proteins on the membrane. Paroxysmal nocturnal hemoglobinuria Hyperphosphatasia with mental retardation syndrome.


PIG-A mutations in normal hematopoiesis. This deficiency on erythrocytes leads to intravascular hemolysis, since certain GPI-anchored proteins i. Chromosomal assignment of genes involved in glycosylphosphatidylinositol anchor biosynthesis: Megaloblastic anemia Pernicious anemia.

All 4 of their aplastic patients who developed PNH had a negative Ham test at diagnosis of aplastic anemia. Sixty patients had died; 28 of the 48 patients for whom the cause of death was known died from either venous thrombosis or hemorrhage. Cerebral venous thrombosisan uncommon form of strokeis more common in those with PNH. Today, the gold standard is flow cytometry for CD55 and CD59 on white and red blood cells.

No PNH-affected cells were found among the erythrocytes or neutrophils of the patients in prolonged remission, but a few PNH-affected lymphocytes were detectable in 3 of the 4 patients tested. PNH is classified by the context under which it is diagnosed: All the patients had clinical disease consistent with PNH hemolytic anemia with some degree of transient or persistent pancytopenia and also erythrocytes with enhanced sensitivity to complement mediated lysis in vitro, as documented by either the Ham test or the sucrose lysis assay.

All 4 patients remained transfusion-independent with no thrombotic episodes after mean follow-up of 30 months. Somatic mutations and cellular selection in paroxysmal nocturnal haemoglobinuria. These results can be compared with historical data reporting a maternal mortality in PNH between 8 and Prior to eculizumab the median life expectancy of an individual with PNH was approximately 10 years. Several of the proteins that anchor to GPI on the cell membrane are used to protect the cell from destruction by the complement systemand, without these anchors, the cells are more easily targeted by the complement proteins.

The gene that codes for PIGA is located on the X chromosomewhich means that only one active copy of the gene for PIGA is present in each cell initially, females have two copies, but one is silenced through X-inactivation.

Hematopoiesis, albeit of an abnormal clone, continues–an example of gene therapy in the wild.